|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:affects
|
cardiovascular safety
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Onglyza
|
|
gptkbp:can_be_combined_with
|
gptkb:diabetes
gptkb:metformin
sulfonylureas
|
|
gptkbp:chemical_formula
|
C18 H25 N3 O2 S
C18 H25 N3 O2
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
glycemic control
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to saxagliptin
|
|
gptkbp:development
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:dosage_form
|
tablets
oral tablet
2.5 mg to 5 mg once daily
2.5 mg or 5 mg once daily
|
|
gptkbp:drug_interactions
|
gptkb:digoxin
other antidiabetic agents
strong CYP3 A4 inhibitors
|
|
gptkbp:effect_on_blood_pressure
|
neutral effect on blood pressure
|
|
gptkbp:effective_date
|
gptkb:2009
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:fdaapproval_type
|
new drug application
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
saxagliptin
|
|
gptkbp:indication
|
improve glycemic control
|
|
gptkbp:ingredients
|
saxagliptin hydrochloride
|
|
gptkbp:interacts_with
|
other diabetes medications
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:lifespan
|
2.5 hours
|
|
gptkbp:marketed_as
|
gptkb:Astra_Zeneca
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
DPP-4 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
bioavailability 67%
|
|
gptkbp:provides_guidance_on
|
EASD guidelines
ADA Standards of Medical Care
|
|
gptkbp:research
|
long-term safety studies
cardiovascular outcomes study
saxagliptin vs placebo
saxagliptin vs sitagliptin
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category B
|
|
gptkbp:safety_measures
|
renal function
|
|
gptkbp:side_effect
|
headache
allergic reactions
skin rash
hypoglycemia
pancreatitis
angioedema
nasopharyngitis
upper respiratory tract infection
upper respiratory tract infections
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
weight neutral
|
|
gptkbp:used_for
|
type 2 diabetes
|
|
gptkbp:bfsParent
|
gptkb:Qtern
|
|
gptkbp:bfsLayer
|
7
|